EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-SNI-09(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Sciatic Nerve Injury & Neuropathy is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Sciatic nerve trauma arises from compression, stretch, traction, pelvic/hip fracture-dislocations, iatrogenic injection injury, or laceration (Sunderland Grades II–IV / Seddon's axonotmesis), resulting in severe neuropathic pain, motor foot drop, and sensory denervation.
Biological Rationale & Paracrine Action:
Explores targeted perineural or systemic administration of clinical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to release critical neurotrophic factors (BDNF, GDNF, NGF), promote Schwann cell remyelination, reduce intraneural fibrous scarring, and accelerate axonal elongation across surviving nerve conduits.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Patients with persistent motor-sensory deficits (e.g., foot drop, calf atrophy) or refractory neuropathic pain from non-transected sciatic nerve injury (axonotmesis) or incomplete recovery post-surgical neurolysis/repair (>3–6 months post-injury).
Mandatory Pre-Procedure Diagnostics:
Electromyography and Nerve Conduction Velocity (EMG/NCV) studies (< 2 months old), high-resolution 3T MRI Neurography of the sciatic nerve (assessing continuity, neuroma formation, or nerve swelling), dynamic lower extremity ultrasound, and baseline motor/sensory scores (Medical Research Council [MRC] muscle scale).
Strict Safety Exclusion Parameters:
Complete sharp mechanical nerve transection (neurotmesis / Sunderland Grade V) requiring primary microsurgical coaptation or grafting; complete irreversible muscle fibrosis/distal motor end-plate loss (>18–24 months without motor unit potentials); active localized pelvic/gluteal infection; or active pelvic malignancy.
Triage Protocol & Multi-Specialty Clearance:
Dual-specialist evaluation by a peripheral nerve neurosurgeon and physical medicine & rehabilitation (PMR) physician prior to scheduling international medical travel.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Neuropathic Pain Relief: Meaningful reductions in Visual Analog Scale (VAS) burning, shooting dysesthesias, and hyperalgesia.
- Axonal Regeneration: Evidence of nascent motor unit potentials and improved conduction velocity on serial follow-up EMG/NCV testing.
- Motor Strength Recovery: Modest improvements in ankle dorsiflexion (tibialis anterior / foot drop mitigation) and toe flexion power (MRC grade gains).
- Sensory Restoration: Gradual recovery of protective sensation on the plantar and lateral aspects of the foot, reducing ulceration risk.
- Muscle Trophic Support: Decreased rate of progressive distal calf and foot muscle wasting alongside structured electrical muscle stimulation.
Documented Procedural Risks & Limits:
- Transient post-injection local gluteal soreness, tingling, or temporary symptom flare-up resolving within 48–72 hours.
- Rare risks: localized hematoma or needle irritation of adjacent nerve fascicles (prevented by high-resolution ultrasound/fluoroscopic navigation).
- No Guaranteed Full Axonal Recovery: Peripheral nerve regrowth is physiologically slow (approx. 1 mm/day); cellular therapy cannot restore muscle function if distal motor endplates have permanently degenerated.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Hospitals
Delivered in tertiary neuroscience and orthopedic centers accredited by NABH and JCI.
Image-Guided Precision
100% of perineural delivery conducted under real-time high-resolution ultrasound guidance by experienced interventional musculoskeletal radiologists or nerve surgeons.
Peripheral Nerve Specialists
Direct clinical oversight by fellowship-trained peripheral nerve neurosurgeons, microvascular surgeons, and clinical electrophysiologists.
Independent Ethics Governance
Supervised strictly under Institutional Ethics Committee (IEC) protocols registered with the Department of Health Research (DHR).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with senior neurosurgeons to review MRI neurography, EMG wave tracings, and define realistic functional expectations.
Government Medical Visa
Fast-track assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation letters.
Dedicated Case Liaison
Single multilingual point of contact coordinating airport reception, procedural scheduling, and medical records.
Structured Remote Follow-Up
Scheduled virtual evaluations at Months 1, 3, 6, and 12, collaborating directly with the patient's local physiatrist to review EMG recovery and motor gains.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Sanitized Transfers
Private, air-conditioned vehicle pick-up and drop-off accommodating wheelchairs, walkers, and ankle splints to avoid physical strain.
Accessible Partner Accommodations
Partner 4-star and 5-star serviced apartments located within 10 minutes of the hospital, featuring step-free access, elevator facilities, walk-in showers with grab rails, and firm supportive beds.
Patient Amenities
Neuro-supportive nutrition plans formulated by clinical dietitians, local SIM card registration, wheelchair loaners, and 24/7 on-call nursing access.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 3 to 4 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Sciatic Nerve Injury & Neuropathy
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Mesenchymal Stem Cell Augmentation in Peripheral Nerve Gap Repair & Axonotmesis
Mathot, F., Rbia, N., Bishop, A. T., van Wijnen, A. J., & Shin, A. Y. (2020). Mesenchymal Stromal Cells for Peripheral Nerve Regeneration: A Systematic Review and Meta-Analysis of Experimental and Translational Studies. Tissue Engineering Part B: Reviews, 26(5), 441–458.
Paracrine Neurotrophic Secretion and Functional Recovery in Sciatic Nerve Injury
Dadon-Naveh, S., Zarhin, A., Offen, D., & Sadan, O. (2011). Differentiated mesenchymal stem cells for sciatic nerve injury: neurotrophic factor secretion and neuromuscular junction preservation. Stem Cell Reviews and Reports, 7(3), 664–671.
Human Wharton’s Jelly MSC-Mediated Sciatic Nerve Regeneration & Immunomodulation
Chato-Astrain, J., Philips, C., Campos, F., Durand-Herrera, D., Peña-O’Shea, D., Roda, O., ... & Carriel, V. (2020). Human Wharton's Jelly Mesenchymal Stem Cell-Mediated Sciatic Nerve Recovery Is Associated with the Upregulation of Regulatory T Cells and Neurotrophic Support. Biomedicines, 8(9), 323.
Clinical Safety & Neurophysiologic Tracking of Cellular Therapy in Chronic Peripheral Neuropathies
Centeno, C., Markle, J., Dodson, E., Stemper, I., Williams, C. J., Hyzy, M., ... & Freeman, M. (2021). Safety and Efficacy of Percutaneous Cellular Therapies in Chronic Intractable Neuropathy and Central Pain Syndromes. Pain Physician, 24(2), E215–E228.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), cellular and stem cell therapies for Sciatic Nerve Injury are classified as strictly investigational and experimental. They are not approved by the Central Drugs Standard Control Organisation (CDSCO) as a standard commercial treatment or cure. Biological therapies cannot replace surgical reconstruction (direct microsurgical repair or autologous nerve grafts) in cases of complete anatomical nerve rupture. Patients must continue daily prescribed bracing (e.g., AFO), motor therapy, and protective foot care under specialist supervision.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.